Abbott Laboratories Stock Performance
Abbott Laboratories shares are trading at $106.20, reflecting a modest daily gain of 0.47% per SID market data. Over the trailing one-month period, ABT has posted a solid gain of $9.84, though the stock remains down 0.86% over the past three months and has declined 16.89% over the past year. From a technical perspective, the stock is trading above both its 50-day moving average of $104.34 and its 200-day moving average of $101.77, suggesting near-term upward momentum, according to SID market data. The 14-day relative strength index stands at 62.4, placing the stock in neutral territory without signaling overbought or oversold conditions. ABT carries a beta of 0.751, indicating lower volatility relative to the broader market. Average daily trading volume stands at approximately 8.88 million shares, supporting consistent liquidity for the $202.5 billion market capitalization healthcare company.
Abbott Laboratories Valuation Analysis
Abbott Laboratories currently trades at a price-to-earnings ratio of 31.15, placing it at a premium relative to the broader healthcare sector, according to SID market data. The company's price-to-book ratio stands at 3.90, reflecting the market's valuation of Abbott's asset base, per SEC filings. The PEG ratio registers at negative 0.58, which is attributable to estimated earnings growth dynamics and limits its utility as a traditional growth-adjusted valuation metric. Abbott offers a dividend yield of 2.06%, providing income-oriented investors with a consistent return component. The company's $202.5 billion market capitalization positions it among the largest players in the diversified healthcare space. These valuation metrics suggest Abbott is priced with expectations of stable cash flow generation and market leadership in its core diagnostics, medical devices, nutrition, and pharmaceutical segments, though the elevated P/E warrants attention relative to sector peers.
Smart Money Activity for ABT
Abbott Laboratories registers a composite smart money score of 51 out of 100, reflecting a neutral signal according to SID market data. Institutional confidence stands at the maximum score of 25 out of 25, indicating strong positioning among large fund managers as reflected in 13F institutional filings. Insider activity scores 12.3 out of 25, with SEC Form 4 filings revealing 17 insider transactions over the past 90 days, comprising 7 purchases and 10 sales. The net selling bias among insiders is notable but not uncommon for large-cap healthcare companies where executives routinely execute pre-planned disposition programs. Dark pool activity scores 8.5 out of 25, suggesting moderate but not elevated off-exchange trading interest. Congressional trading activity registers at 5.3 out of 25, indicating limited disclosed positions among members of Congress. The divergence between strong institutional conviction and more tempered insider and dark pool signals produces the overall neutral composite reading for Abbott.
Abbott Laboratories Earnings Outlook
Abbott Laboratories has demonstrated consistent earnings execution across recent quarters, according to company earnings reports. In the most recently completed quarter, Abbott reported earnings per share of $1.42, matching the consensus analyst estimate precisely with zero surprise. The prior quarter showed EPS of $1.31 against estimates of $1.28, delivering a positive surprise of $0.03. The quarter before that produced EPS of $1.15 versus estimates of $1.14, representing a $0.01 beat. This pattern reflects a sequential earnings acceleration from $1.15 to $1.31 to $1.42, indicating strengthening operational performance across the reporting periods. Analysts currently estimate $1.42 EPS for the upcoming quarter, per analyst estimates, projecting flat sequential performance. Abbott's ability to meet or exceed consensus in each of the last three reported quarters underscores management's execution discipline and supports the reliability of forward estimates across its diversified healthcare portfolio.
Wall Street Analyst Ratings for ABT
Wall Street analyst sentiment on Abbott Laboratories remains predominantly constructive, though a recent downgrade introduces a notable dissenting view, per Wall Street analyst reports. On October 27, 2026, Argus Research downgraded ABT from Buy to Hold, marking the sole negative revision in the latest cycle. This contrasts with maintained positive ratings from several major firms: Wells Fargo reiterated its Overweight rating on October 23, while TD Cowen maintained a Buy rating on October 22. JP Morgan also reaffirmed its Overweight stance on October 22, and Baird maintained an Outperform rating on the same date, according to SID consensus data. The four-to-one ratio of positive-to-neutral ratings among recent analyst actions suggests broad confidence in Abbott's fundamental trajectory despite Argus Research's more cautious positioning. The clustering of maintained ratings around the October earnings report date indicates that quarterly results largely confirmed existing investment theses across the analyst community covering the diversified healthcare company.
